<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20150704023046N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-02-08</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of fibrinogen compared to fresh frozen plasma on patients with hemorrhagic shock</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the fibrinogen and fresh frozen plasma efficacy in patients outcome with hemorrhagic shock due to multiple trauma</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/35729</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Accidental randomization was done using randomized blocking method in which subjects were assigned to three main groups (two intervention groups and one control group) (each group was 10) and the volume of blocks was 4 Which was determined through the PROC PLAN in SAS 9.2 software, Blinding description: Blindness in this study is that after evaluating an emergency medicine practitioner and determining the patient's placement in one of our three study groups, the injectable drug will be given to the nurse of the CPR department, and then the order of assessment of the patient's vital signs will be researcher Emergency medicine), which has no information on how to describe the patient's placement and type of injectable medicine, is given according to the protocol.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Hemorrhagic shock. Condition 2: Hypovolemic shock.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients receiving Packed Cell and Frozen Fresh Plasma in proportion (FFP: 1: 1 PRbc Ratio). Intervention is performed for each patient at one time in the emergency CPR room. Each packed cell is approximately 200-250 cc and each frozen plasma unit is 200-300 cc. Intervention 2: Intervention group: Patients receiving Packed Cell and Fibrinogen. The amount of fibrinogen injection will be 70 mg / kg. The fibrinogen vial is made in Germany and will be provided by Avin Daru Company in Iran. Interventions are performed for each patient at one time and in the emergency CPR room. Intervention 3: Control group: Patients receiving Packed Cell. The Packed Cell available at the Blood Bank Center of the studied hospitals was used. The size of each Packed Cell is approximately 200-250 cc. The number of Packed Cell varies depending on the patient's needs and clinical conditions. Intervention is performed for each patient at one time and in the emergency CPR room.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only part of the information, such as information on the main outcome or the like, can be shared.

When:
Start the access period 6 months after printing the results

To whom:
Researchers working in academic and academic institutions and industry-related people

Conditions:
Solely for the sake of scientific use and only with the permission of the owners of the design

Where to obtain:
Responsible person is responsible for studying and by email registered on the site

How to obtain:
So coordinate with the responsible person responsible for the study through email registered on the site

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ehsan Karimpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz Jundishapur University of Medical Sciences - Golestan</address>
        <city>Ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>61357-15794</zip>
        <telephone>+98 61 3222 2818</telephone>
        <email>Dr.EhsanKarimpour@Gmail.Com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Meysam Moezi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz Jundishapur University of Medical Sciences - Golestan</address>
        <city>Ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>61357-15794</zip>
        <telephone>+98 61 3222 2818</telephone>
        <email>Dr.EhsanKarimpour@Gmail.Com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with hemorrhagic shock caused by multiple trauma
Age&gt; 14 years
Systolic blood pressure &lt;90 mm Hg
Significant chance of bleeding
Evidence of intra abdominal bleeding
Clinical judgment of the doctor about the receipt of blood products</inclusion_criteria>
      <agemin>14 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
Patients with known coagulopathy
Using anti-coagulant and anti-platelet drugs
Other causes of shock, such as neurogenic shock
Previous history of blood product in the last 6 months
Patients are severely ill, whose priority is to preserve the patient's health
Dissatisfaction with the patient or patient companions to participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R58</hc_code>
      <hc_code>R57.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hemorrhage, not elsewhere classified</hc_keyword>
      <hc_keyword>Hypovolemic shock</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients receiving Packed Cell and Frozen Fresh Plasma in proportion (FFP: 1: 1 PRbc Ratio). Intervention is performed for each patient at one time in the emergency CPR room. Each packed cell is approximately 200-250 cc and each frozen plasma unit is 200-300 cc.</i_keyword>
      <i_keyword>Intervention group: Patients receiving Packed Cell and Fibrinogen. The amount of fibrinogen injection will be 70 mg / kg. The fibrinogen vial is made in Germany and will be provided by Avin Daru Company in Iran. Interventions are performed for each patient at one time and in the emergency CPR room.</i_keyword>
      <i_keyword>Control group: Patients receiving Packed Cell. The Packed Cell available at the Blood Bank Center of the studied hospitals was used. The size of each Packed Cell is approximately 200-250 cc. The number of Packed Cell varies depending on the patient's needs and clinical conditions. Intervention is performed for each patient at one time and in the emergency CPR room.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood Pressure. Timepoint: 4 and 12 hours after admission, 24-hour short-term prognosis, 7-day mid-term and long-term 28-day. Method of measurement: Clinical examination and assessment of vital signs by cardiac monitoring and pulse oximetry located in the cardiopulmonary resuscitation room.</prim_outcome>
      <prim_outcome>Oxygenation index. Timepoint: 4 and 12 hours after admission, 24-hour short-term prognosis, 7-day mid-term and long-term 28-day. Method of measurement: pulse oximetry located in the cardiopulmonary resuscitation room.</prim_outcome>
      <prim_outcome>PH level. Timepoint: 4 and 12 hours after admission, 24-hour short-term prognosis, 7-day mid-term and long-term 28-day. Method of measurement: By taking arterial blood samples and evaluating arterial blood gas by laboratory tests.</prim_outcome>
      <prim_outcome>Duration of admission. Timepoint: When ordering a patient's discharge or issuing a death certificate. Method of measurement: Clinical examination and evaluation of patient records.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-08-29</approval_date>
        <contact_name>The Ethics Committee of Ahvaz Jundishapur University of Medical Sciences</contact_name>
        <contact_address>Ahwaz Jundishapur Research and Technology Dept, Ahvaz Jundishapur University of Medical Sciences, Golestan, Ahvaz Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
